Insertion site analyses
Genomic DNA was extracted with QIAamp DNA Blood Mini kit or Micro kit (QIAGEN) and integration sites (IS) were collected from magnetic beads-isolated BM or PB cell types through LAM-PCR and high-throughput Illumina sequencing as previously described. (1, 2) The diversity index for each sample and time point was estimated on the basis of richness (number of unique integration sites marking individual clones) and evenness (relative clonal contribution in terms of sequence reads associated to each integration site). (2)
WASP mean fluorescence intensity (MFI) in platelets
The MFI of WASP expression in platelets was calculated on total CD41a+ platelet gate. Data were acquired at Canto II flow cytometer and analysed using Flow Jo Software. The ratio between patient and control MFI was calculated. Peripheral blood from healthy controls was obtained in accordance with the 1964 Helsinki declaration and its later amendments or ethical standards. Informed consent was approved by the Institutional Ethical Committee of San Raffaele Hospital in 2009 (Tiget Periblood protocol). Twenty-three healthy controls have been recruited.
Study populations
Eczema score before gene therapy is reported in Table 1 for all patients who received this treatment (n=8). Eczema was described as mild in 5 patients, moderate in 2 or severe in 1 patient. In figure 3E , the graph shows the eczema score before GT and at 3 years of follow up in the 6 patients with follow up ≥3 years after treatment. Among them, 3 had mild eczema before gene therapy.
The term gastrointestinal bleeding includes all clinically observable bleeding events involving gastrointestinal tract, such as bloody diarrhoea and blood streaks in stools. These events were classified according to common toxicity criteria (CTC) criteria and attributed a grade from 1 (mild) to 4 (life-threatening). 
Recently, a slightly revised version of the disease score has been proposed, including the definition of a distinct WAS subgroup with the respect to Severe Refractory Thrombocytopenia, that should be considered a characteristic of severe disease with the assignment of a score 5 if present under the age of 2 years (7).
In the original protocol, the presence of a revertant cell population in T cells represented an exclusion criterion, as WASP expression in revertant T cells was not distinguishable from the expression driven by the gene therapy vector. Afterwards, in 2014 the protocol was amended to remove this exclusion criterion to allow inclusion also of patients with such characteristics, since we thought that this criterion was no longer justified. First, WASP expression from the vector had been shown in all previously treated WAS patients after gene therapy, in multiple cell lineages. Second, since older patients carry more frequently a revertant population, maintenance of this criterion would have excluded from gene therapy several patients without a compatible HSC donor and that might have benefited from this treatment. Finally, the presence of a higher background in WASP expression in T cells in patients is accounted in the analyses of WASP expression. (the x-and y-axis scale is not the same for all patients and depends on the duration of follow up and maximum platelet count, respectively). Red bar represents the length of transfusion dependence after treatment. During this interval, platelet counts were censored because they were not representative of patients' own platelet production. Only platelet counts >7 days after platelet transfusions were included in the analysis after treatment. As regards the period before gene therapy, platelet counts in the 3 months before starting the treatment phase were collected with the largest feasible time interval from platelet transfusions, whose frequency was determined by clinical need. G-CSF administered on days 42 and 44 for delayed neutrophil recovery thought to be caused by intense response to the conditioning regimen and concomitant infection. Notes: Patients 1, 2 and 3 have been described previously.
14 The target cumulative busulfan AUC was 36,000-48,000 ng x h/mL for the first 6 treated patients. Following a protocol amendment, the target cumulative busulfan AUC was changed to 48,000 (±10%) ng x h/mL for the final 2 treated patients. Cumulative AUC was estimated as (AUC1+AUC6)x4 for patients who received 8 doses of busulfan and (AUC1+AUC6)x4+D9xAUC6/D5 for patients who received 9 doses of busulfan.
Table S2
Total Day -14 0ꞏ00 0ꞏ01 0ꞏ01 0ꞏ00 0ꞏ00 0ꞏ00 0ꞏ00 0ꞏ00
Day +1 0ꞏ00 0ꞏ00 0ꞏ00 0ꞏ00 0ꞏ00 0ꞏ00 0ꞏ00 0ꞏ00
Day +14 0ꞏ00 0ꞏ02 0ꞏ02 0ꞏ00 0ꞏ00 0ꞏ00 0ꞏ00 0ꞏ00
Day +30 0ꞏ00 0ꞏ06 0ꞏ09 0ꞏ00 0ꞏ00 0ꞏ03 0ꞏ00 0ꞏ00 nd, not done. Serum immunoglobulin level before gene therapy (at screening) and after gene therapy (at last available follow up), at least 3 months after stopping immunoglobulin replacement therapy) is reported. In bold are reported normal values for age (according to Burgio GR, Perinotto G, Ugazio AG 1991). IgM level improved in all patients after gene therapy, although it did not reach normal level for age in all. na, not available (patients still on immunoglobulin replacement therapy or <3 months since stopping replacement therapy). § Ongoing immunoglobulin replacement therapy.
Table S5 -Antibody response to vaccination
In the table are reported specific antibody levels after 3 doses of hexavalent vaccination, 2 doses of Pneumovax® or 2-3 doses of Prevenar® vaccine, received by patients >3 months after ceasing IVIG supplementation. Specific antibody response after vaccination was performed at Immunologische Tagesklinik in Wien (Austria). Pt2, Pt6 and Pt9 were vaccinated after data cut off. After data cut off, the 5 patients reported in the table received measles, mumps and rubella (MMR) vaccine and 2 of them also varicella (VZV) vaccination, showing protective antibody titers when tested. *After data cut off. °After one dose of Pneumovax® and one dose of Prevenar®. nd -Not yet evaluable data about antibody response to Prevenar® (ongoing).
